Psychedelic Stocks Archives - Page 56 of 61

WednesdayMar 09, 2022 1:17 pm

Colorado May Soon Decriminalize Psilocybin Mushrooms

Psychedelics were made illegal when the Controlled Substances Act of 1970 was enacted, with most of the substances being classified as Schedule I. Substances under this category are considered to have a high potential for abuse with no current accepted medical use. However, recent studies have shown that naturally derived psychedelics, including DMT, ibogaine and mescaline, which have been used by various communities for hundreds of years, possess the potential to heal a number of indications. These clinical trials and studies have shown that psychedelics such as psilocybin have the potential to treat post-traumatic stress disorder, end-of-life anxiety and severe…

TuesdayMar 08, 2022 3:18 pm

Dr. Bronner’s to Provide Employees with Ketamine-Assisted Therapy

In a recent press release, Dr. Bronner’s revealed that it had broadened its mental healthcare coverage as the first step in its strategy to provide access to psychedelic-assisted therapy to its employees as a means to promote mental health. This plan, which includes the use of ketamine in combination with therapy, is to be administered by Enthea, a not-for-profit healthcare organization that is responsible for benefit plan administration, provider network management and medical policy development. The organization also establishes quality-of-care standards for provided treatments, including the management of a specialty provider network. Dr. Bronner’s is collaborating with Enthea because both…

MondayMar 07, 2022 12:13 pm

Signs the Psychedelics Renaissance Is Here to Stay

It seems psychedelics are here to stay, what with the developments being seen in different parts of the country. These natural substances were being used by Indigenous communities way before the West began to embrace the use of drugs such as LSD in the ‘50s. During this period before the drugs were banned in 1970, significant research looking into psychedelic-assisted therapy was conducted, with numerous studies showing their potential in the treatment of addiction, anxiety and depression. Recently, we’ve seen psychedelics go mainstream again, thanks to new clinical trials and studies that have convinced regulatory bodies, including the U.S. FDA…

FridayMar 04, 2022 12:43 pm

Utah Legislators Advance Approved Psychedelics Bill to Governor’s Desk

Last week, legislators in the state of Utah sent a measure to the governor that would establish a task force to conduct research on the therapeutic potential of various psychedelic substances and make recommendations on potential regulations for their legal use. The bill, which was introduced by Rep. Brady Brammer, was passed by both the House and Senate, with 68 to 1 and 23 to 1 votes respectively. It remains unclear where the state’s governor, Gov. Spencer Cox, stands on this issue. The recommendations made by the panel on these substances, which are defined as controlled substances under the Controlled…

ThursdayMar 03, 2022 2:17 pm

How Investors Can Cash In on the Boom in the Psychedelic Field

The psychedelic sector has seen major growth in the past few years as consumer interest in psychedelic drugs as alternative medicines has increased. As research into psychedelics picks up steam and lawmakers discuss legalizing the substances, industry experts project that the psychedelics industry will experience significant growth over the next decade. Last year was a pretty good year for the nascent sector, and a new report indicates the industry could reach even greater highs in 2022. For investors who are looking to diversify their portfolio and invest in an emerging industry, psychedelics present an attractive opportunity. According to the Defiance…

WednesdayMar 02, 2022 2:16 pm

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Teams Up with Chopra Foundation to Foster Psychedelics Therapy Awareness

Dr. Deepak Chopra recently stated that there was an urgent need for more effective treatments in the mental health space, a statement with which Doug Drysdale, CEO of Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), agrees. Drysdale stated that he believed that the largest barrier in the advancement of the flourishing psychedelics industry was the stigmatization and misinformation concerning psychedelic compounds. He explained that many individuals who weren’t involved in the psychedelics sector knew so little about these compounds and had warped perceptions about what they could do, giving the example of a conversation he had with one scientist who…

TuesdayMar 01, 2022 2:18 pm

Study Finds Psilocybin Use Lowers Odds of Being Arrested

A new study has linked the use of psilocybin with a reduction in the likelihood of an individual engaging in criminal behavior. Psilocybin is the active compound found in hallucinogenic mushrooms. Harvard University clinical psychology PhD candidate Grant Jones, the author of the study, stated that his interest in psychedelics grew as the substances gained more attention because of their treatment potential, having demonstrated that they could be used to relieve a number of mental health conditions. Jones explained that the purpose of the research was to investigate the relationship between criminality and psychedelics using population-based survey data, because not…

MondayFeb 28, 2022 10:29 am

At-Home Ketamine Treatments for Mental Disorders Boom in US

Ketamine for the treatment of various mental health conditions, particularly depression, is growing in the United States. However, while the ease of prescription rules is fueling increases in drug offerings, some experts are concerned that this may cause a regulatory crackdown, as the long-term impact of this particular anesthetic hasn’t been well studied. Boris Heifets, an assistant professor of anesthesiology at Stanford University, explained that it would be better if the drug was slowly rolled out to better implement a much more integrated approach to mental health. Ketamine, which was once a taboo party drug, has been available in the…

ThursdayFeb 24, 2022 3:50 pm

VIU Set to Launch First Psychedelics Therapy Course in Canada

Vancouver Island University (“VIU”) plans to launch its psychedelic-assisted therapy course in September of this year. This will make it the first accredited university in Canada to offer this course for healthcare professionals, under its Faculty of Health and Human Services. Shannon Dames, the institution’s nursing professor, stated that this launch was significant because it recognized that psychedelic-assisted therapy was an advanced practice that required a unique skill set. Laura McLean, one of the program’s registrants, signed up after she tried therapy under Roots to Thrive. Roots to Thrive is a 12-week program with virtual sessions that feature guided discussions…

WednesdayFeb 23, 2022 2:31 pm

A Review of Recent Moves Made by Psychedelic Companies

A lot has happened over the past weeks in the psychedelics industry. Below, we look at some of the moves companies in this burgeoning sector have made. Last week, Core One Labs Inc. researchers at its Vocan Biotechnologies Inc. subsidiary had received positive results and would begin using its recombinant production system to produce API-Grade N-methyltryptamine, or NMT. NMT is also known as MMT, or monomethyl tryptamine, and is a DMT precursor that the company will be producing to expand its psychedelic product pipeline. The firm is currently using its proprietary recombinant production system to produce psilocybin. In a recent…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Psychedelic Stocks